Individual Login
Log in
You will be redirected to aap.org to login or to create your account.
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women
Jump to section
Related Articles
Cited By...
- Antibody binding to native cytomegalovirus glycoprotein B predicts vaccine efficacy
- Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans
- Ongoing inadequacy of quadrivalent HPV vaccine safety studies
- Opportunistic HPV vaccination at age 16-23 and cervical screening attendance in Sweden: a national register-based cohort study
- 4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years
- A Population-Based Study of Sociodemographic and Geographic Variation in HPV Vaccination
- Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD
- Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine
- Immunogenicity and Safety of a 9-Valent HPV Vaccine
- Skin and Mucosal Human Papillomavirus Seroprevalence in Persons with Fanconi Anemia
- Human papillomavirus vaccination for boys
- Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease
- Long-term Study of a Quadrivalent Human Papillomavirus Vaccine
- Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study
- "Time-Expanded" HPV Vaccine Schedules Provide Protection
- Adherence to the HPV Vaccine Dosing Intervals and Factors Associated With Completion of 3 Doses
- Safety, Tolerability, and Immunogenicity of Gardasil Given Concomitantly With Menactra and Adacel
- Should boys receive the human papillomavirus vaccine? Yes
- Human papillomavirus prevalence and type distribution in penile carcinoma
- Vaccination against human papillomavirus
- Intention of parents to have male children vaccinated with the human papillomavirus vaccine
- The Case for a Gender-Neutral (Universal) Human Papillomavirus Vaccination Policy in the United States: Point
- Will vaccination against human papillomavirus prevent eye disease? A review of the evidence
- Prophylactic HPV vaccines
- Human papillomavirus vaccines launch a new era in cervical cancer prevention
- How Effective Is the Quadrivalent HPV Vaccine at Preventing High-grade Cervical Lesions?
- HPV Vaccine for Preadolescents and Adolescent Boys and Girls